VULTUS AB (V06) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VULTUS AB (V06) has a cash flow conversion efficiency ratio of -14.938x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€25.38 Million ≈ $29.67 Million USD) by net assets (€-1.70 Million ≈ $-1.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of VULTUS AB to measure how much of total assets are equity-financed.
VULTUS AB - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how VULTUS AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check V06 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
VULTUS AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VULTUS AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spectra7 Microsystems Inc
V:SEV
|
-0.792x |
|
ARMATURA S.A.
RO:ARM
|
-0.001x |
|
QUADRO RESOURCES LTD
F:G4O
|
-0.026x |
|
Baring Emerging Europe Plc
LSE:BEMO
|
0.014x |
|
Goldhills Holding Ltd
V:GHL
|
0.008x |
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
0.057x |
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
-0.001x |
|
Universal Ibogaine Inc
V:IBO
|
-0.405x |
Annual Cash Flow Conversion Efficiency for VULTUS AB (2021–2025)
The table below shows the annual cash flow conversion efficiency of VULTUS AB from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see V06 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €34.63 Million ≈ $40.48 Million |
€24.72 Million ≈ $28.90 Million |
0.714x | +181.79% |
| 2024-12-31 | €2.47 Million ≈ $2.89 Million |
€-2.16 Million ≈ $-2.52 Million |
-0.873x | +37.60% |
| 2023-12-31 | €5.20 Million ≈ $6.08 Million |
€-7.27 Million ≈ $-8.50 Million |
-1.399x | -82.31% |
| 2022-12-31 | €7.06 Million ≈ $8.26 Million |
€-5.42 Million ≈ $-6.34 Million |
-0.767x | -10.26% |
| 2021-12-31 | €3.53 Million ≈ $4.13 Million |
€-2.46 Million ≈ $-2.87 Million |
-0.696x | -- |
About VULTUS AB
C100 AB (publ) is public investment firm specializing in early stage and Emerging stage. The Firm prefers to invest in Technology and Life science Sector. The Firm Typically focuses on early-stage biotech platforms, emerging digital health technologies, transformative software solutions for the investments. C100 AB (publ) is based in stockholm, Sweden.